NCT03291158撤回1 期
A Phase 1, Randomized, Open-Label Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Minocin (Minocylcine) for Injection
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)1 个研究点 分布在 1 个国家开始时间: 2018年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Analyze plasma, ELF and Alveolar Macrophage concentrations of minocycline
研究概览
简要总结
This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.
详细描述
The purpose of this study is to evaluate the safety of Minocin IV and measure plasma, epithelial lining fluid, and alveolar macrophage drug levels after six doses of Minocin IV given 12 hours apart, administered as 1-hour infusions in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A signed informed consent form, the ability to understand the study conduct and tasks that are required for study participation, and a willingness to cooperate with all tasks, tests, and examinations as required by the protocol, whether in the hospital or after discharge, for the duration of the study;
- •Healthy adult male or female between 18 and 55 years of age (inclusive) at the time of Screening;
- •Body mass index (BMI) ≥ 18.5 and ≤ 30 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive) at Screening;
- •Subject is in good health based on medical history and physical examination findings and has no clinically meaningful safety laboratory abnormalities (hematology, blood chemistry, and urinalysis) or 12-lead ECG results, as assessed by the Principal Investigator (PI);
- •Vital signs (blood pressure [BP], pulse, and temperature) measured at Screening/baseline must be within the following ranges: systolic BP ≥90 to ≤150 mm Hg, diastolic BP ≥45 to ≤90 mm Hg; Heart Rate ≥ 45 to ≤90 bpm (taken after resting in a supine position for at least 5 minutes);
- •Expectation that intravenous access will be sufficient to allow for ease of study drug infusion and for all protocol-required blood sampling to take place;
- •Subject commits to remaining under observation of the study staff for the course of the study;
- •Female subject is surgically sterile (bilateral tubal occlusion), postmenopausal, or if of childbearing potential, agrees to abstinence or to use a highly efficient method of birth control (i.e., intrauterine device [IUD] or intrauterine hormone-releasing system [IUS] or vasectomized male partner, or hormonal contraceptives [estrogen and progestogen combined or progestogen only] with inhibition of ovulation; oral hormonal contraceptives must be supplemented with the use of condoms), between inclusion and for 7 days after the completion of the study;
- •If male, agree to be sexually abstinent or agree to use an approved method of contraception (e.g., condom with spermicide) when engaging in sexual activity from study check-in through 7 days after completion of the study, and to not donate sperm during this same period of time.
排除标准
- •Has any condition, including findings in the medical history or in pre-study assessments that constitutes a risk or a contraindication for the participation in the study or completing the study;
- •Any acute illness, including clinically significant infection within 30 days prior to Day 1;
- •Surgery within the past three months prior to Day 1 determined by the PI to be clinically relevant;
- •Positive breath test for alcohol on Day 1 (pre-dose) and/or positive urine test for drugs of abuse at Screening/Day -1 visit;
- •Has a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse is defined as regularly consuming >3 units/day (21 units per week for men) and >2 units/day (14 units/week) for women. A unit is defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), or a glass of wine (100 mL);
- •Subject is a smoker and smokes >5 cigarettes per day (or equivalent);
- •Use of non-tobacco/nicotine-containing products within 6 months prior to Day 1;
- •Current diagnosis of or positive at Screening for HIV and/or Hepatitis B;
- •Blood or plasma donation within past 2 months;
- •Females who are pregnant or nursing or who have a positive pregnancy test result at Screening;
- •Presence of known raised intracranial pressure;
- •Use of isotretinoin;
- •History of significant hypersensitivity or allergic reaction to tetracycline antibiotics;
- •History of allergic or other serious adverse reactions to lidocaine;
- •Clinically significant pulmonary or any other disease that prevents a subject from undergoing bronchoscopy with bronchopulmonary lavage;
- •History of seizures (e.g., epilepsy), head injury, or meningitis requiring ongoing anti-seizure medications;
- •Receipt of any investigational medication or investigational device during the last 30 days prior to randomization;
- •Vigorous exercise from 48 hours prior to Day -1 until the day of discharge from the study;
- •Treatment with any prescription or over-the-counter drugs, within two weeks of day 1, with the exception of acetaminophen/paracetamol for minor headache. Birth control or other hormone replacement is also permitted as long as it has been taken at a stable dose for at least three months before the Screening visit and remains stable for the duration of the study;
- •Unable or unwilling to comply with the protocol;
- •An employee of the PI or study center with direct involvement in the proposed study or other studies under the direction of that PI or study center, or a family member of the employee or the PI
研究组 & 干预措施
Minocycline IV
Experimental
Open label Minocin IV
干预措施: Minocycline (Drug)
结局指标
主要结局
Analyze plasma, ELF and Alveolar Macrophage concentrations of minocycline
时间窗: 16 weeks
Determine plasma ELF and Alveolar Macrophage concentrations of minocycline when administered to healthy adult subjects.
次要结局
- Safety and Tolerability(16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
MEDI5752 in Japanese Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT05685472AstraZeneca6
已完成
1 期
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerAdvanced Lung CancerNCT04672356Innovent Biologics (Suzhou) Co. Ltd.19
已完成
1 期
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLCAdvanced Lung CancerNCT04672369Innovent Biologics (Suzhou) Co. Ltd.42
已完成
1 期
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT03394144AstraZeneca11
已完成
1 期
A Phase I Study of MEDI9447 (Oleclumab) in Japanese PatientsAdvanced Solid MalignanciesNCT03736473AstraZeneca6